Search hospitals

>

California

>

Duarte

City of Hope Comprehensive Cancer Center

Claim this profile

Duarte, California 91010

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Breast Cancer

Conducts research for Lymphoma

Conducts research for Solid Tumors

2114 reported clinical trials

157 medical researchers

Photo of City of Hope Comprehensive Cancer Center in DuartePhoto of City of Hope Comprehensive Cancer Center in DuartePhoto of City of Hope Comprehensive Cancer Center in Duarte

Summary

City of Hope Comprehensive Cancer Center is a medical facility located in Duarte, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Lymphoma, Solid Tumors and other specialties. City of Hope Comprehensive Cancer Center is involved with conducting 2,114 clinical trials across 1,167 conditions. There are 157 research doctors associated with this hospital, such as Daneng Li, MD, Anna Pawlowska, MD, Mark Agulnik, and Vincent Chung, MD.

Area of expertise

1

Cancer

Global Leader

City of Hope Comprehensive Cancer Center has run 382 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Lung Cancer

Global Leader

City of Hope Comprehensive Cancer Center has run 267 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
EGFR positive

Top PIs

Clinical Trials running at City of Hope Comprehensive Cancer Center

Prostate Cancer

Breast Cancer

Skin Cancer

Breast cancer

Kidney Cancer

Cancer

Lung Cancer

Pancreatic Cancer

Multiple Myeloma

Testicular cancer

Image of trial facility.

Ifinatamab Deruxtecan

for Prostate Cancer

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Recruiting

2 awards

Phase 3

30 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at City of Hope Comprehensive Cancer Center?

Where is City of Hope Comprehensive Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does City of Hope Comprehensive Cancer Center accept?

What awards or recognition has City of Hope Comprehensive Cancer Center received?